Ankeet Bhatt, MD, MBA, ScM

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 891-5921 (phone)
ankeet.s.bhatt@kp.org

Ankeet S. Bhatt, MD, MBA, ScM is a research scientist at the Division of Research and an associate physician and practicing cardiologist and intensivist at the Kaiser Permanente San Francisco Medical Center. Dr. Bhatt's research interests include cardio-renal-metabolic disease, with a particular focus on clinical trials, heart failure, shock, and implementation and care delivery science.

Dr. Bhatt earned his undergraduate degree in biological sciences at the University of Connecticut, where he completed both medical and business training in a joint MD/MBA program. He completed his residency at the Duke University Hospital in Durham, NC, followed by fellowships in cardiovascular diseases and critical care medicine at the Brigham and Women's Hospital and Harvard Medical School in Boston, MA. He completed a 2-year research fellowship under the mentorship of Drs. Scott Solomon, David Morrow, Marc Pfeffer, and Muthiah Vaduganathan at Harvard Medical School and earned a Master of Science in Epidemiology from the Harvard T.H. Chan School of Public Health.

Dr. Bhatt has presented his research at national and international scientific congresses and participates in the leadership of several large implementation science trials in cardiovascular disease. He has authored more than 60 peer-reviewed manuscripts and currently serves as the Section Editor of Implementation & Care Delivery Science for the Journal of Cardiac Failure.

Current Position(s):

Research Scientist, Division of Research, Kaiser Permanente Northern California, Oakland, CA
Associate Physician, Department of Cardiology, Kaiser San Francisco Medical Center, San Francisco, CA

Section Affiliations:

Primary Research Interests:

Implementation and Care Delivery Science
Clinical Trials
Heart Failure
Cardiogenic Shock
Cardiometabolic Disease

Studies

Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake (NUDGE-FLU)

NUDGE-FLU was a nationwide, pragmatic, registry-based, cluster-randomized implementation trial during the 2022-23 influenza season in Denmark. NUDGE FLU randomized >960,000 Danish citizens aged 65 years or older to usual care or 9 different behaviorally informed electronic letters (9:1:1:1:1:1:1:1:1:1) promoting influenza vaccination. Letters explaining the potential cardiovascular benefits of influenza vaccination demonstrated a modest but significant improvement in vaccination uptake, a finding which was particularly pronounced in patients without vaccination in the prior influenza season, potentially indicating the ability to nudge a vaccine hesitant group.
Investigator: Bhatt, Ankeet
Funder: Sanofi Pasteur S.A.

TRANSFORM3: Evaluation of Implementation Strategies of Teaching, Technology, and Teams to Optimize Medical Therapy in Cardiovascular Disease ("T3")

This initiative evaluates strategies (including technology-based decision support, referral to a virtual guideline-directed medical therapy team, and general educational tools/resources for clinicians and patients) to improve use of guideline-directed therapeutics known to lower cardiovascular events among patients with heart failure, atrial fibrillation and type 2 diabetes/ arteriosclerotic cardiovascular disease.
Investigator: Bhatt, Ankeet
Funder: American College of Cardiology Foundation

Coronary Artery Risk Development in Young Adults (CARDIA)

This landmark 35-year study describes the distribution of coronary heart disease risk factors in a biracial cohort of men and women aged 18 to 30 years at entry; and identifies habits, behaviors and lifestyles that are associated with initial levels of risk factors, with the evolution of risk factors, and increasingly with clinical events.
Investigator: Bhatt, Ankeet
Funder: National Heart, Lung, and Blood Institute

Highlighted Publications

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic.

Author(s): Bhatt, Ankeet S; Moscone, Alea; McElrath, Erin E; Varshney, Anubodh S; Claggett, Brian L; Bhatt, Deepak L; Januzzi, James L; Butler, Javed; Adler, Dale S; Solomon, Scott D; Vaduganathan, Muthiah

J Am Coll Cardiol. 2020 Jul 21;76(3):280-288. doi: 10.1016/j.jacc.2020.05.038. Epub 2020 May 26.

Current Position(s):

Section Affiliations:

Primary Research Interests:

Studies

Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake (NUDGE-FLU)

TRANSFORM3: Evaluation of Implementation Strategies of Teaching, Technology, and Teams to Optimize Medical Therapy in Cardiovascular Disease ("T3")

Coronary Artery Risk Development in Young Adults (CARDIA)

Highlighted Publications

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic.

Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory.

Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study.

Prioritizing Dissemination and Implementation Science in Cardiometabolic Medicine: CONNECTing the Dots.

Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America.

De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry.

Evaluating Digital Technologies for Implementation Science

Publications

The Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: a Prespecified Analysis of the NUDGE-FLU Trial.

Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial.

Virtual Care Team-Guided Therapeutic Optimization During Hospitalization in Patients with Heart Failure: The IMPLEMENT-HF Study.

Strategic transformations in academic clinical medicine.

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Adverse Remodeling and Reverse Remodeling After Myocardial Infarction.

Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).

Achieving a Maximally Tolerated beta-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?

Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.

Curious Crosses: Injection-Induced Lesions.

Improving operating room turnover time: a systems based approach.

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic.

Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.

International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.

Influenza Vaccination in Patients With Heart Failure.

Reply: Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease.

Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.

Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure.

Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Discovery and care innovation amidst a pandemic.

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019.

Clinical Outcomes in Young US Adults Hospitalized With COVID-19.

A Man in His 30s With a New Continuous Murmur and Fever.

Growing Mismatch Between Evidence Generation and Implementation in Heart Failure.

Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong.

Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19.

Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory.

Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches.

Practice pattern of use of high sensitivity troponin in the outpatient settings.

Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients?

Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.

Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients.

Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study.

Influenza vaccination: a 'shot' at INVESTing in cardiovascular health.

For vaptans, as for life, balance is better.

Incidence and Outcomes of Pneumonia in Patients With Heart Failure.

Reply: Improving Heart Failure Therapeutics: Thinking Outside the Pillbox?

Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.

Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization.

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.

Evidence-Based Prescribing and Polypharmacy for Patients With Heart Failure.

Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization?

Prioritizing Dissemination and Implementation Science in Cardiometabolic Medicine: CONNECTing the Dots.

Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19.

Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America.

Adherence to Evidence-Based Therapies in Heart Failure: Deepening the Implementation Divide.

Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.

Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry.

De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry.

The cardiovascular legacy of the COVID-19 pandemic.

Prioritizing prevention of de novo and worsening chronic heart failure.

Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network.

Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.

Reply: Bounded Rationality and Clinical Guidance Documents for Heart Failure.

Personalizing Comprehensive Disease-Modifying Therapy: Obstacles and Opportunities.

Relationship Between Myocardial Injury During Index Hospitalization for SARS-CoV-2 Infection and Longer-Term Outcomes.

Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.

Building a Curriculum for the Cardiovascular Implementation Scientist.

Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries.

Vaccines, Antibodies and Donors: Varying Attitudes and Policies Surrounding COVID-19 and Heart Transplantation.

Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry.

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction

Evaluating Digital Technologies for Implementation Science

Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States